Abstract:Introduction Emerging molecular evidence implicates mitochondrial dysfunction, systemic inflammation, and capillary rarefaction as pivotal contributors to the pathophysiology of HFpEF. Photobiomodulation (PBM) has garnered attention for its potential to augment mitochondrial metabolism, attenuate inflammation, and foster angiogenesis. This investigation aims to delineate the effects of PBM on the pathophysiology of HFpEF in a murine model. Methods To induce HFpEF, 3-month-old male C57BL/6 mice were subjected to a '2-hit model' involving a high-fat diet combined with the vasoconstrictor nitric oxide synthase inhibitor, N(G)-Nitro-L-arginine methyl ester (L-NAME). PBM therapy was administered transdermally over the cardiac region thrice weekly for a duration of 10 weeks using a 904nm super-pulsed laser, with each session lasting 90 seconds and delivering an energy density of 4.2J/cm^2 per diode to a cohort of 12 mice. A sham group of 13 mice underwent identical procedures with the laser deactivated. An additional control group of 10 mice was maintained on a standard diet without any interventions. Echocardiographic assessments were performed at the outset, 7th and 10th week time. Following the 10-week period, mice were euthanized, their hearts harvested and serum withdrawn for further analysis. Results Echocardiography of PBM-treated animals demonstrated significant attenuation of deterioration of diastolic parameters (E') compared to the sham-treated control group (E'[mm/sec], baseline-vs-10w: PBM, -32.1±5.9-vs- -27.9±6.4; sham, -32.9±8.6-vs- -22.5±5.7; p=0.037). Histological analysis of the cardiac tissue involving picrosirius red staining for collagen revealed that the HFpEF model induced a significant increase in the standardized adventitial collagen compared to controls, which was attenuated by PBM (control 3.0±1.6; HFpEF sham: 3.9±1.8; PBM: 3.4±1.9, p=0.008 control vs sham, p=0.055 PBM vs control; p=0.396 control vs PBM). Multiplex analysis of HFpEF mice showed significantly higher levels of inflammatory chemokines than controls that were attenuated by PBM (mean±SD log[pg/ml] of the chemokine (C-X-C motif) ligand-1 (CXCL-1): PBM=2.52±0.29, Control=2.14±0.35; monocyte chemotactic protein (MCP-1): PBM=0.87±0.46, HFpEF=1.5±0.58, Control=0.8±0.6; p<0.001 and p=0.003 respectively). RNA sequencing revealed 551 genes with significant differential expression (DE) between PBM and Controls (adjusted p-value [padj]<0.1). Ingenuity Pathway Analysis (IPA) analysis revealed that PBM upregulated genes pertaining to mitochondrial metabolism and down-regulated genes active in mitochondrial dysfunction (qPCR [GAPDH] 2–∆∆Ct fold change PBM/Sham: Ndufv2=3.7, Atp5md=3.5, Dnhd1=0.5). Relevant DE genes were validated by quantitative real-time PCR (qPCR). Conclusions PBM attenuated Diastolic dysfunction, fibrosis, pro-inflammatory chemokine secretion and upregulates mitochondrial metabolism in a mouse model of HFpEF.Study designResults

Rational design of powder formulations for tamp filling processes

Berberine Promotes Cardiac Function by Upregulating PINK1/Parkin-Mediated Mitophagy in Heart Failure.

Berberine Attenuates Adverse Left Ventricular Remodeling and Cardiac Dysfunction after Acute Myocardial Infarction in Rats: Role of Autophagy

Berberine improves dietary-induced cardiac remodeling by upregulating Kruppel-like factor 4-dependent mitochondrial function

Hydrogen sulfide alleviates heart failure with preserved ejection fraction in mice by targeting mitochondrial abnormalities via PGC-1α

Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy.

Berberine inhibits cardiac remodeling of heart failure after myocardial infarction by reducing myocardial cell apoptosis in rats

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Identification of myosin heavy chain in Saccharomyces cerevisiae

Photobiomodulation mitigates diastolic dysfunction, reduces perivascular fibrosis and inflammation, and enhances mitochondrial metabolism and angiogenesis in a mouse model of HFpEF

Berberine Ameliorates High Glucose-Induced Cardiomyocyte Injury via AMPK Signaling Activation to Stimulate Mitochondrial Biogenesis and Restore Autophagic Flux

Berberine ameliorates chronic intermittent hypoxia‐induced cardiac remodelling by preserving mitochondrial function, role of SIRT6 signalling

Berberine Attenuates Hepatic Steatosis and Enhances Energy Expenditure in Mice by Inducing Autophagy and Fibroblast Growth Factor 21

Improvement of Endothelial Dysfunction of Berberine in Atherosclerotic Mice and Mechanism Exploring through TMT-Based Proteomics

FBXL4 Protects Against HFpEF Through Drp1-Mediated Regulation of Mitochondrial Dynamics and the Downstream SERCA2a

Blunted Cardiac Mitophagy in Response to Metabolic Stress Contributes to HFpEF

Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action

Berberine plays a cardioprotective role by inhibiting macrophage Wnt5a/β‐catenin pathway in the myocardium of mice after myocardial infarction

Activation Of Amp-Activated Protein Kinase Is Required For Berberine-Induced Reduction Of Atherosclerosis In Mice: The Role Of Uncoupling Protein 2

Hydrogen Sulfide Attenuates Cardiac Dysfunction in a Rat Model of Heart Failure: a Mechanism Through Cardiac Mitochondrial Protection